Literature DB >> 31229669

Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.

Lisa Ehmann1, Michael Zoller2, Iris K Minichmayr1, Christina Scharf2, Wilhelm Huisinga3, Johannes Zander4, Charlotte Kloft5.   

Abstract

Effective antibiotic dosing is vital for therapeutic success in critically ill patients. This work aimed to develop an algorithm to identify appropriate meropenem dosing in critically ill patients. Population pharmacokinetic (PK) modelling was performed in NONMEM®7.3 based on densely sampled meropenem serum samples (npatients = 48; nsamples = 1376) and included a systematic analysis of 27 pre-selected covariates to identify factors influencing meropenem exposure. Using Monte Carlo simulations newly considering the uncertainty of PK parameter estimates, standard meropenem dosing was evaluated with respect to attainment of the pharmacokinetic/pharmacodynamic (PK/PD) target and was compared with alternative infusion regimens (short-term, prolonged, continuous; daily dose, 2000-6000 mg). Subsequently, a dosing algorithm was developed to identify appropriate dosing regimens. The two-compartment population PK model included three factors influencing meropenem pharmacokinetics: the Cockcroft-Gault creatinine clearance (CLCRCG) on meropenem clearance; and body weight and albumin on the central and peripheral volume of distribution, respectively; of these, only CLCRCG was identified as a vital influencing factor on PK/PD target attainment. A three-level dosing algorithm was developed (considering PK parameter uncertainty), suggesting dosing regimens depending on renal function and the level (L) of knowledge about the infecting pathogen (L1, pathogen unknown; L2, pathogen known; L3(-MIC), pathogen and susceptibility known; L3(+MIC), MIC known). Whereas patients with higher CLCRCG and lower pathogen susceptibility required mainly intensified dosing regimens, lower than standard doses appeared sufficient for highly susceptible pathogens. In conclusion, a versatile meropenem dosing algorithm for critically ill patients is proposed, indicating appropriate dosing regimens based on patient- and pathogen-specific information.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Dosing algorithm; Intensive care; Pharmacokinetics/pharmacodynamics; Renal function; β-Lactams

Year:  2019        PMID: 31229669     DOI: 10.1016/j.ijantimicag.2019.06.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  21 in total

1.  In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.

Authors:  N J Onufrak; N M Smith; M J Satlin; J B Bulitta; X Tan; P N Holden; R L Nation; J Li; A Forrest; B T Tsuji; Z P Bulman
Journal:  Clin Microbiol Infect       Date:  2020-05-05       Impact factor: 8.067

2.  Interaction of Staphylococcus aureus and Acinetobacter baumannii during In Vitro β-Lactam Exposure.

Authors:  Nicholas M Smith; Alexa Ang; Fanny Tan; Katelyn Macias; Sarah James; Jasleen Sidhu; Justin R Lenhard
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Model-Informed Therapeutic Drug Monitoring of Meropenem in Critically Ill Patients: Improvement of the Predictive Ability of Literature Models with the PRIOR Approach.

Authors:  Anna Chan Kwong; Amaury O'Jeanson; Sonia Khier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-04-08       Impact factor: 2.441

4.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.

Authors:  Laura Evans; Andrew Rhodes; Waleed Alhazzani; Massimo Antonelli; Craig M Coopersmith; Craig French; Flávia R Machado; Lauralyn Mcintyre; Marlies Ostermann; Hallie C Prescott; Christa Schorr; Steven Simpson; W Joost Wiersinga; Fayez Alshamsi; Derek C Angus; Yaseen Arabi; Luciano Azevedo; Richard Beale; Gregory Beilman; Emilie Belley-Cote; Lisa Burry; Maurizio Cecconi; John Centofanti; Angel Coz Yataco; Jan De Waele; R Phillip Dellinger; Kent Doi; Bin Du; Elisa Estenssoro; Ricard Ferrer; Charles Gomersall; Carol Hodgson; Morten Hylander Møller; Theodore Iwashyna; Shevin Jacob; Ruth Kleinpell; Michael Klompas; Younsuck Koh; Anand Kumar; Arthur Kwizera; Suzana Lobo; Henry Masur; Steven McGloughlin; Sangeeta Mehta; Yatin Mehta; Mervyn Mer; Mark Nunnally; Simon Oczkowski; Tiffany Osborn; Elizabeth Papathanassoglou; Anders Perner; Michael Puskarich; Jason Roberts; William Schweickert; Maureen Seckel; Jonathan Sevransky; Charles L Sprung; Tobias Welte; Janice Zimmerman; Mitchell Levy
Journal:  Intensive Care Med       Date:  2021-10-02       Impact factor: 17.440

5.  Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.

Authors:  Yaru Peng; Zeneng Cheng; Feifan Xie
Journal:  Antimicrob Agents Chemother       Date:  2022-08-25       Impact factor: 5.938

6.  Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.

Authors:  Ferdinand Anton Weinelt; Miriam Songa Stegemann; Anja Theloe; Frieder Pfäfflin; Stephan Achterberg; Franz Weber; Lucas Dübel; Agata Mikolajewska; Alexander Uhrig; Peggy Kiessling; Wilhelm Huisinga; Robin Michelet; Stefanie Hennig; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2022-06-02

7.  Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.

Authors:  David Busse; Philipp Simon; Lisa Schmitt; David Petroff; Christoph Dorn; Arne Dietrich; Markus Zeitlinger; Wilhelm Huisinga; Robin Michelet; Hermann Wrigge; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2021-12-11       Impact factor: 5.577

8.  Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Ze-Ming Wang; Xiao-Yu Chen; Wei Zhao; A-Dong Shen; Jing Bi; Mei-Ying Wang; Bao-Ping Xu; Bo-Hao Tang; Cen Li
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

9.  Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients.

Authors:  Uwe Liebchen; Ferdinand Weinelt; Jette Jung; Robin Michelet; Christina Scharf; Ines Schroeder; Michael Paal; Michael Zoller; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

10.  The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis.

Authors:  Ahmed A Abulfathi; Veronique de Jager; Elana van Brakel; Helmuth Reuter; Nikhil Gupte; Naadira Vanker; Grace L Barnes; Eric Nuermberger; Susan E Dorman; Andreas H Diacon; Kelly E Dooley; Elin M Svensson
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.